Rallies from the big miners and health care stocks helped lift the Australian share market last week.
The benchmark S&P/ASX 200 rose 0.33% to 6,195 points, while the broader All Ordinaries index gained 0.25% to close at 6,281 points.
Key domestic data released last week was Australia’s official unemployment rate, which dropped to an eight-year low of 4.9% in February.
AMP Capital Chief Economist Shane Oliver said this was largely due to fewer people looking for a job, and as a result the job figures “added nothing” to the debate about whether the RBA would cut rates or not.
“Employment slowed but this was after a huge surge in January, so (this) could just be noise,” he added.
The major miners were among the strongest performers last week, with BHP adding more than $3.3 billion in market value and Rio Tinto gaining $935 million in value.
Aristocrat Leisure also led gains, with the gambling machine manufacturer adding more than $1 billion to its market capitalisation, following a positive broker note from Deutsche Bank.
The note said Aristocrat continued to win market share in a stable US gaming market, and that its shares were trading significantly lower than the target price, in a sign that it could be a bargain for investors.
Meanwhile, the health care stocks performed well, with aged care operator Estia Health’s shares jumping by nearly 18% to $2.85, and shares in diagnostic imaging provider Healius rising about 6% to $2.79.
Commonwealth Bank was among the biggest losers on the share market last week, with the country’s biggest bank shedding more than $1.5 billion in value.
Sydney Airport also took a hit, with a loss of almost $632 million to its market value after the company reported a 1.5% fall in total passenger numbers for February, compared to a year ago.
The airport’s CEO Geoff Culbert said reduced domestic seat capacity and lower load factors were behind the fall.
“In addition, cancellation rates for the month continue to be higher than usual,” Mr Culbert said.
ASX 200 Listed Companies – Top 5 Biggest Market Cap Gains and Losses (15/03/2019 to 22/03/2019) | |||||||||
Biggest Gains | Biggest Losses | ||||||||
Rank | Company | $ Change in Market Cap | Closing Share Price | % Change in Share Price | Rank | Company | $ Change in Market Cap | Closing Share Price | % Change in Share Price |
1 | BHP Group (BHP) | $3,328,812,075 | $37.61 | 3.1% | 1 | Commonwealth Bank (CBA) | -$1,557,810,766 | $71.43 | -1.2% |
2 | Aristocrat Leisure (ALL) | $1,040,826,964 | $24.82 | 7.0% | 2 | New Hope Corporation (NHC) | -$964,269,261 | $3.25 | -26.3% |
3 | RIO Tinto (RIO) | $935,464,859 | $94.17 | 2.7% | 3 | St Barbara (SBM) | -$634,391,625 | $3.29 | -26.9% |
4 | CSL (CSL) | $570,899,413 | $197.19 | 0.6% | 4 | Sydney Airport Holdings (SYD) | -$631,982,228 | $7.15 | -3.8% |
5 | Transurban Group (TCL) | $561,812,653 | $12.86 | 1.7% | 5 | REA Group (REA) | -$496,564,416 | $75.71 | -4.7% |
Prepared by Canstar. Prices taken as of week to week close. |
Gold miner St Barbara downgraded its production guidance last week, leading to a sharp fall in its share price that wiped $634 million from its market value.
Vehicle fleet management company Eclipx Group’s shares tumbled by a massive 60.5%, after it announced that its trading conditions have continued to deteriorate since its last update in January.
On top of this, the company has advised that a merger with administrative services provider McMillan Shakespeare is unlikely to proceed.
ASX 200 Listed Companies – Top 5 Biggest Share Price Gains and Losses (15/03/2019 to 22/03/2019) | |||||||
Biggest Gains | Biggest Losses | ||||||
Rank | Company | Closing Share Price | % Change | Rank | Company | Closing Share Price | % Change |
1 | Estia Health (EHE) | $2.85 | 17.3% | 1 | Eclipx Group (ECX) | $0.75 | -60.5% |
2 | Nanosonics (NAN) | $4.56 | 9.4% | 2 | St Barbara (SBM) | $3.29 | -26.9% |
3 | Aristocrat Leisure (ALL) | $24.82 | 7.0% | 3 | New Hope Corporation (NHC) | $3.25 | -26.3% |
4 | Corp Travel (CTD) | $25.13 | 6.5% | 4 | Nufarm (NUF) | $4.63 | -13.6% |
5 | Healius (HLS) | $2.79 | 6.1% | 5 | Platinum Asset (PTM) | $4.86 | -12.0% |
Prepared by Canstar. Prices taken as of week to week close. |
Try our Online Share Trading comparison tool to instantly compare Canstar expert rated options.
This advice is general and has not taken into account your objectives, financial situation, or needs. It is not personal advice. Consider whether this advice is right for you, having regard to your own objectives, financial situation and needs. You may need financial advice from a suitably qualified adviser. For more information, read Canstar’s Financial Services and Credit Guide (FSCG) and our detailed disclosure. Canstar may receive a fee for referring you to a product provider – for further information, see how we get paid. Payment of fees for ads does not influence our Star Ratings or Awards.
Canstar is a comparison website, not a product issuer, so it’s important to check any product information directly with the provider. Consider the Product Disclosure Statement (PDS), Target Market Determination (TMD) and other applicable product documentation before making a decision to purchase, acquire, invest in or apply for a financial or credit product. Contact the product issuer directly for a copy of the PDS, TMD and other documentation.
Canstar is an information provider and in giving you product information Canstar is not making any suggestion or recommendation about a particular credit product or loan. If you decide to apply for a credit product or loan, you will deal directly with a credit provider, and not with Canstar. Rates and product information should be confirmed with the relevant credit provider. For more information, read the credit provider’s key facts sheet and other applicable loan documentation for that product. Read the Comparison Rate Warning.
All information about performance returns is historical. Past performance should not be relied upon as an indicator of future performance; unit prices and the value of your investment may fall or rise.
Canstar is an information provider and in giving you product information Canstar is not making any suggestion or recommendation about a particular product. The information has been prepared without taking into account your individual investment objectives, financial circumstances or needs. Before you decide whether or not to acquire a particular financial product you should assess whether it is appropriate for you in the light of your own personal circumstances, having regard to your own objectives, financial situation and needs. You may wish to obtain financial advice from a suitably qualified adviser before making any decision to acquire a financial product. Please refer to the product disclosure statement (PDS) and Canstar’s Financial Services and Credit Guide (FSCG) for more information, and read our detailed disclosure, important notes and liability disclaimer.
All information about performance returns is historical. Past performance should not be relied upon as an indicator of future performance; unit prices and the value of your investment may fall or rise.
Canstar may earn a fee for referrals from its website tables, and from Sponsorship or Promotion of certain products. Fees payable by product providers for referrals and Sponsorship or Promotion may vary between providers, website position, and revenue model. Sponsorship or Promotion fees may be higher than referral fees. Sponsored or Promotion products are clearly disclosed as such on website pages. They may appear in a number of areas of the website such as in comparison tables, on hub pages and in articles. Sponsored or Promotion products may be displayed in a fixed position in a table, regardless of the product's rating, price or other attributes. The table position of a Sponsored or Promoted product does not indicate any ranking or rating by Canstar. For more information please see How We Get Paid.
Any advice provided on this website is general and has not taken into account your objectives, financial situation or needs. Consider whether this advice is right for you. Consider the Product Disclosure Statement and Target Market Determination before making a purchase decision. Canstar provides an information service. It is not a credit provider, and in giving you information about credit products Canstar is not making any suggestion or recommendation to you about a particular credit product. Research provided by Canstar Research AFSL and Australian Credit Licence No. 437917. You must not reproduce, transmit, disseminate, sell, or publish information on this website without prior written permission from Canstar.